Cover Image
Market Research Report

Pain Relieving Drugs Market Forecast 2017-2027: Neuropathic Pain Relieving Drugs, Narcotic Pain Relieving Drugs, Non-Narcotic Pain Relieving Drugs, Anti-Arthritic Pain Relieving Drugs, Anti-Migraine Pain Relieving Drugs

Published by Visiongain Ltd Product code 204742
Published Content info 306 Pages
Delivery time: 1-2 business days
Price
Back to Top
Pain Relieving Drugs Market Forecast 2017-2027: Neuropathic Pain Relieving Drugs, Narcotic Pain Relieving Drugs, Non-Narcotic Pain Relieving Drugs, Anti-Arthritic Pain Relieving Drugs, Anti-Migraine Pain Relieving Drugs
Published: December 15, 2016 Content info: 306 Pages
Description

The global pain relieving drugs market is expected to grow at a CAGR of 2.1% from 2021-2027. The market is expected to grow from $67.8bn in 2016 to $75.2bn in 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 306-page report you will receive 122 tables and 121 charts - all unavailable elsewhere.

The 306 page report provides clear detailed insight into the global pain relieving drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

image1

Report Scope

  • Global Pain Relieving Drugs Market forecasts from 2017-2027
  • Pain Relieving Drugs National Market forecasts from 2017-2027, covering:
    • United States
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Japan
    • Brazil
    • China
    • Russia
    • India
    • Rest of the World
  • Global Pain Relieving Drugs submarkets and their leading drugs forecasts from 2017-2027 covering:
    • Narcotic Pain Relieving Drugs
    • Non-Narcotic Pain Relieving Drugs
    • Neuropathic Pain Relieving Drugs
    • Anti-Migraine Pain Relieving Drugs
    • Anti-Arthritic Pain Relieving Drugs
  • Analysis of the key factors driving and restraining the growth of the pain relieving drugs market from 2017-2027

Visiongain's study is intended for anyone requiring commercial analyses for the pain relieving drugs market. You find data, trends and predictions.

Table of Contents
Product Code: PHA0157

Table of Contents

1. Report Overview

  • 1.1 Global Pain Relieving Drugs: Market Overview
  • 1.2 Global Pain Relieving Drugs Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. An Introduction to Pain and Pain Management

  • 2.1 Pain: A Sensory and Emotional Phenomenon
    • 2.1.1 Pain: A Short History
    • 2.1.2 Pain Pathways and the Origin of Pain
  • 2.2 The World Health Organisation (WHO) Pain Ladder
    • 2.2.1 Classification of Pain
      • 2.2.1.1 Acute Pain
      • 2.2.1.2 Chronic Pain
  • 2.3 The Psychosocial Effects of Chronic Pain
    • 2.3.1 Chronic Cancer Pain
    • 2.3.2 Neuropathic Pain
    • 2.3.3 Identifying Neuropathic Pain
  • 2.4 The Neurochemistry of Pain
    • 2.4.1 Prostaglandins
    • 2.4.2 Opioids
  • 2.5 Pain Management - A Brief Overview
  • 2.6 Pain Management Drugs
    • 2.6.1 The Use of Opioids in Pain Treatment
    • 2.6.2 OTC Pain Relievers
  • 2.7 Market Definition

3. World Pain Relieving Drugs Market 2017-2027

  • 3.1 Global Pain Relieving Drugs: Market Overview
    • 3.1.1 Categorisation of the Global Pain Relieving Drug Market
    • 3.1.2 Pain Relieving Drugs: A Growing Market
  • 3.2 The Global Pain Relieving Drugs Market in 2016
    • 3.2.1 Market Dominance of Arthritic Pain Relieving Drugs
  • 3.3 Global Pain Relieving Drugs: Market Forecast 2017-2027
    • 3.3.1 Market Sectors That Will Drive Growth
    • 3.3.2 Abuse Deterrents and Safety Measures Will Boost Narcotic Pain Relieving Drugs Market Growth
    • 3.3.3 Changing Market Shares by Sector 2016-2027

4. Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2017-2027

  • 4.1 The Global Narcotic Pain Relieving Drugs Market in 2016
    • 4.1.1 Global Narcotic Pain Relieving Drugs: Market Forecast 2016-2027
    • 4.1.2 Changing Market Shares By Leading Drugs 2016-2027
  • 4.2 Opana ER (Endo Pharmaceuticals): Market Analysis
    • 4.2.1 Tamper-Proof Opana ER Products
    • 4.2.2 Opana ER: Historical Sales Analysis, 2014-2016
    • 4.2.3 Opana ER: Sales Forecast 2016-2027
  • 4.3 Duragesic: Market Analysis
    • 4.3.1 Duragesic: Historical Sales Analysis, 2014-2016
    • 4.3.2 Duragesic: Sales Forecast 2016-2027
  • 4.4 Oxycontin ER: Market Analysis
    • 4.4.1 Tamper Resistant Oxycontin ER
    • 4.4.2 Oxycontin ER: Patent Expiries and Legal Battles
    • 4.4.3 Oxycontin ER: Sales Forecast 2016-2027
  • 4.5 Ultram: Market Analysis
    • 4.5.1 Ultram: Sales Forecast 2016-2027
  • 4.6 Zaldiar/Ixprim: Market Analysis
    • 4.6.1 Zaldiar/Ixprim: Historical Sales Analysis, 2014-2016
    • 4.6.2 Zaldiar/Ixprim: Sales Forecast 2016-2027
  • 4.7 Other Narcotic Pain Relieving Drugs
    • 4.7.1 Subsys (Insys Therapeutics)
    • 4.7.2 Oxecta (Pfizer)
    • 4.7.3 Other Narcotic Pain Relieving Drugs: Sales Forecast 2016-2027

5. Non-Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2017-2027

  • 5.1 The Global Non-Narcotic Pain Relieving Drugs Market in 2016
    • 5.1.1 Global Non-Narcotic Pain Relieving Drugs: Market Forecast 2016-2027
    • 5.1.2 Changing Market Shares by Leading Drugs 2016-2027
  • 5.2 Aspirin (Bayer): Market Analysis
    • 5.2.1 Aspirin (Bayer): Historical Sales Analysis, 2014-2016
    • 5.2.2 Aspirin (Bayer): Sales Forecast 2016-2027
  • 5.3 Panadol: Market Analysis
    • 5.3.1 Panadol: Historical Sales Analysis, 2014-2016
    • 5.3.2 Panadol: Sales Forecast 2016-2027
  • 5.4 Advil: Market Analysis
    • 5.4.1 Advil: Historical Sales Analysis, 2014-2016
    • 5.4.2 Advil: Sales Forecast 2016-2027
  • 5.5 Tylenol: Market Analysis
    • 5.5.1 Tylenol: Sales Forecast 2016-2027
  • 5.6 Other Non-Narcotic Pain Drugs
    • 5.6.1 Exparel (Pacira Pharmaceuticals)
    • 5.6.2 Other Non-Narcotic Pain Drugs: Sales Forecast 2016-2027

6. Neuropathic Pain Relieving Drugs: World Market Analysis and Forecast, 2017-2027

  • 6.1 An Introduction to Neuropathic Pain
    • 6.1.1 Identifying Neuropathic Pain
    • 6.1.2 Pharmacological Interventions for Neuropathic Pain
      • 6.1.2.1 Analgesics in Neuropathic Pain
      • 6.1.2.2 Anti-Convulsants
      • 6.1.2.3 Local Anaesthetics
      • 6.1.2.4 Anti-Depressants
      • 6.1.2.5 Aldose Reductase Inhibitors
    • 6.1.3 The Global Neuropathic Pain Relieving Drugs Market in 2016
    • 6.1.4 Global Neuropathic Pain Relieving Drugs: Market Forecast 2016-2027
    • 6.1.5 Changing Market Shares by Leading Drugs 2016-2027
  • 6.2 Lidoderm: Market Analysis
    • 6.2.1 Lidoderm Patent Expiry and Endo Pharma - Watson/Actavis Agreement
    • 6.2.2 Lidoderm Marketing Probe
    • 6.2.3 Lidoderm: Historical Sales Analysis, 2014-2016
    • 6.2.4 Lidoderm: Sales Forecast 2016-2027
  • 6.3 Lyrica: Market Analysis
    • 6.3.1 Lyrica: Historical Sales Analysis, 2014-2016
    • 6.3.2 Lyrica: Sales Forecast 2016-2027
  • 6.4 Cymbalta: Market Analysis
    • 6.4.1 Cymbalta: Historical Sales Analysis, 2014-2016
    • 6.4.2 Cymbalta: Sales Forecast 2016-2027
  • 6.5 Neurontin: Market Analysis
    • 6.5.1 Neurontin: Historical Sales Analysis, 2014-2016
    • 6.5.2 Neurontin: Sales Forecast 2016-2027
  • 6.6 Nucynta: Market Analysis
    • 6.6.1 Nucynta: Historical Sales Analysis, 2014-2016
    • 6.6.2 Nucynta: Sales Forecast 2016-2027
  • 6.7 Other Neuropathic Pain Relieving Drugs
    • 6.7.1 Retigabine (GSK; Valeant)
    • 6.7.2 Other Neuropathic Pain Relieving Drugs: Sales Forecast 2016-2027

7. Anti-Migraine Drugs: World Market Analysis and Forecast, 2017-2027

  • 7.1 Migraine: An Introduction
    • 7.1.1 Management of Migraine
    • 7.1.2 Drugs Being Used in the Treatment of Migraine
    • 7.1.3 Other Migraine Relieving Techniques
    • 7.1.4 The Global Anti-Migraine Pain Relieving Drugs Market in 2016
    • 7.1.5 Global Anti-Migraine Pain Relieving Drugs: Market Forecast 2016-2027
    • 7.1.6 Changing Market Shares by Leading Drugs 2016-2027
  • 7.2 Relpax: Market Analysis
    • 7.2.1 Relpax: Historical Sales Analysis, 2014-2016
    • 7.2.2 Relpax: Sales Forecast 2016-2027
  • 7.3 Maxalt: Market Analysis
    • 7.3.1 Maxalt: Historical Sales Analysis, 2014-2016
    • 7.3.2 Maxalt: Sales Forecast 2016-2027
  • 7.4 Imitrex/Imigran: Market Analysis
    • 7.4.1 Imitrex/Imigran: Historical Sales Analysis, 2014-2016
    • 7.4.2 Imitrex/Imigran: Sales Forecast 2016-2027
  • 7.5 Zomig: Market Analysis
    • 7.5.1 Zomig: Licensing Transfers and Exclusivity
    • 7.5.2 Zomig: Historical Sales Analysis, 2014-2016
    • 7.5.3 Zomig: Sales Forecast 2016-2027
  • 7.6 Botox (Allergan): Market Analysis
    • 7.6.1 Botox: Historical Sales Analysis, 2014-2016
    • 7.6.2 Botox: Sales Forecast 2016-2027
  • 7.7 Treximet: Market Analysis
    • 7.7.1 Treximet: Agreements Between GSK, Pozen Pharmaceuticals and Pernix Therapeutics
    • 7.7.2 The Generic Treats to Treximet
    • 7.7.3 Treximet: Historical Sales Analysis, 2014-2016
    • 7.7.4 Treximet: Sales Forecast 2016-2027
  • 7.8 Axert: Market Analysis
    • 7.8.1 Axert: Historical Sales Analysis, 2014-2016
    • 7.8.2 Axert: Sales Forecast 2016-2027
  • 7.9 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast, 2016-2027
  • 7.10 Anti-Migraine Pain Relieving Drugs Market - Future Prospects
    • 7.10.1 Unmet Needs in the Treatment of Migraine

8. Anti-Arthritic Pain Drugs: World Market Analysis and Forecast, 2017-2027

  • 8.1 Understanding Arthritis: An Introduction to its Aetiology and Prevalence
    • 8.1.1 Management of Arthritic Conditions
    • 8.1.2 Drugs Being Used In the Treatment Of Arthritis
      • 8.1.2.1 Analgesics as Pain Relieving Drugs
      • 8.1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
      • 8.1.2.3 Corticosteroids
      • 8.1.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDS)
    • 8.1.3 Biological Drugs in the Treatment of Arthritis
      • 8.1.3.1 Biologics Used for Rheumatoid Arthritis
      • 8.1.3.2 The Potential Side Effects of Biologics in the Treatment of Arthritis
    • 8.1.4 The Global Anti-Arthritis Pain Relieving Drugs Market in 2016
    • 8.1.5 Global Anti-Arthritis Pain Relieving Drugs: Market Forecast 2016-2027
    • 8.1.6 Changing Market Shares by Leading Drugs, 2016-2027
  • 8.2 Humira: Market Analysis
    • 8.2.1 Humira: Historical Sales Analysis, 2014-2016
    • 8.2.2 Humira: Sales Forecast 2016-2027
  • 8.3 Enbrel: Market Analysis
    • 8.3.1 Enbrel: Co-Promotions and Marketing Rights
    • 8.3.2 Enbrel: Historical Sales Analysis, 2014-2016
    • 8.3.3 Enbrel: Patent Expiries and Potential Competition, 2016-2027
    • 8.3.4 Enbrel: Sales Forecast 2016-2027
  • 8.4 Remicade: Market Analysis
    • 8.4.1 Remicade: Historical Sales Analysis, 2014-2016
    • 8.4.2 Remicade: Patent Expiries and Potential Competition, 2016-2027
    • 8.4.3 Remicade: Sales Forecast 2016-2027
  • 8.5 Voltaren: Market Analysis
    • 8.5.1 Voltaren: Historical Sales Analysis, 2014-2016
    • 8.5.2 Voltaren: Sales Forecast 2016-2027
  • 8.6 Rituxan (Rituximab, MabThera): Market Analysis
    • 8.6.1 Rituxan: Historical Sales Analysis, 2014-2016
    • 8.6.2 Rituxan: Patent Expiries and Potential Competition, 2016-2027
    • 8.6.3 Rituxan: Sales Forecast 2016-2027
  • 8.7 Celebrex: Market Analysis
    • 8.7.1 Celebrex: Historical Sales Analysis, 2014-2016
    • 8.7.2 Celebrex: Patents, Exclusivity, and Competition, 2016-2027
    • 8.7.3 Celebrex: Sales Forecast 2016-2027
  • 8.8 Arcoxia: Market Analysis
    • 8.8.1 Arcoxia: Historical Sales Analysis, 2014-2016
    • 8.8.2 Arcoxia: Sales Forecast 2016-2027
  • 8.9 Other Anti-Arthritis Pain Relieving Drugs
    • 8.9.1 Duexa (Horizon Pharma)
    • 8.9.2 Lodotra/RAYOS (Horizon Pharma; Skyepharma)
    • 8.9.3 Ofatumumab (Genmab, GSK)
    • 8.9.4 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast 2016-2026
  • 8.10 Anti-Arthritic Pain Relieving Drug Market - Future Prospects

9. Leading National Markets for Pain Relieving Drugs, 2017-2027

  • 9.1 The Pain Relieving Drug Market by Region
    • 9.1.1 The Global Distribution of Pain Relieving Drugs In 2016
  • 9.2 Leading National Markets: Forecast, 2016-2027
    • 9.2.1 Changing Market Shares by Region, 2016-2027
  • 9.3 Regional Pain Relieving Drugs Markets: Analysis and Forecasts, 2016-2027
  • 9.4 United States: The Largest Pain Relieving Drug Market
  • 9.5 The EU5 Markets
    • 9.5.1 EU5 Markets: Changing Market Shares by Country, 2016-2027
    • 9.5.2 Germany
    • 9.5.3 UK
    • 9.5.4 France
    • 9.5.5 Italy
    • 9.5.6 Spain
  • 9.6 Japan
  • 9.7 China
  • 9.8 Brazil
  • 9.9 India
  • 9.10 Russia
  • 9.11 Rest of the World

10. Pain Relieving Drugs: R&D Pipeline 2017-2027

  • 10.1 Innovative Products Currently In Development Will Drive Growth
    • 10.1.1 Large Developmental Pipelines Encouraged By High Potential Growth
  • 10.2 Development Pipeline for Narcotic Pain Relieving Drugs
    • 10.2.1 Remoxy (Durect, Pain Therapeutics, Pfizer)
    • 10.2.2 MoxDuo IR (Shire; China Aoxing; QRxPharma)
    • 10.2.3 ALO-02 (Pfizer)
    • 10.2.4 DETERx - COL-003 (Collegium Pharmaceuticals)
    • 10.2.5 Acurox (Acura; Pfizer)
    • 10.2.6 Morphine-6-Glucuronide (Paion)
    • 10.2.7 Acuracet (Acura)
    • 10.2.8 ARX-02 (AcelRx Pharmaceuticals)
    • 10.2.9 Zohydro ER (Zogenix)
    • 10.2.10 BEMA Buprenorphine (BioDelivery Sciences; Endo Pharmaceuticals)
    • 10.2.11 Rapidly Acting Topical Analgesic (Vapogenix Inc)
    • 10.2.12 VB100 (Vitality Biopharma Inc)
    • 10.2.13 VB210 (Vitality Biopharma Inc)
  • 10.3 Development Pipeline for Non-Narcotic Pain Relieving Drug
    • 10.3.1 Lofexidine Hydrochloride (US World Meds)
    • 10.3.2 Synera (Nuvo Research)
    • 10.3.3 Neosaxitoxin (Proteus SA; Boston Children Hospital)
    • 10.3.4 OMS103 (Omeros)
    • 10.3.5 Tetrodotoxin (CK Life Sciences; WEX Pharmaceuticals)
  • 10.4 Development Pipeline for Neuropathic Pain Relieving Drugs
    • 10.4.1 Perampanel (Eisai)
    • 10.4.2 Serenbotase (Syntaxin, Ipsen, Allergan)
    • 10.4.3 EMA401 (Spinifex Pharmaceuticals)
    • 10.4.4 Ralfinamide (Newron)
    • 10.4.5 NT-11624 (Neurotune)
    • 10.4.6 AmiKet (Immune Pharmaceuticals)
    • 10.4.7 Eladur (Durect; Impax Laboratories)
    • 10.4.8 Clonidine Gel (Arcion Therapeutics; BioDelivery Sciences)
    • 10.4.9 AVP-923 (Avanir Pharmaceuticals)
    • 10.4.10 ARC-2022 (Arcion Therapeutics)
    • 10.4.11 TV-45070 Topical (Teva Pharmaceuticals)
    • 10.4.12 LX9211 (Lexicon Pharmaceuticals)
  • 10.5 Development Pipeline for Anti-Migraine Pain Relieving Drugs
    • 10.5.1 Zecuity (NuPathe; Teva)
    • 10.5.2 Lasmiditan (CoLucid Pharmaceuticals)
    • 10.5.3 NXN-188 (NeurAxon)
    • 10.5.4 Levadex/Semprana (Allergan)
    • 10.5.5 ALD403(Alder Biopharmaceuticals Inc)
  • 10.6 Development Pipeline for Anti-Arthritis Pain Relieving Drugs
    • 10.6.1 Zavryl/Ibuprofen-PC (PLx Pharma)
    • 10.6.2 Naproxcinod (NicOx)
    • 10.6.3 Xeljanz (Pfizer)
    • 10.6.4 Masitinib (AB Science)
    • 10.6.5 Belimumab (GSK, Human Genome Sciences)
    • 10.6.6 Fasinumab (Teva Pharmaceuticals)
  • 10.7 What Does the Future Hold for Pain Relieving Drugs Research and Development?
  • 10.8 Solubility: A Hindrance to Drug Development
  • 10.9 Monoclonal Antibodies (MAbs) - Potential Novel Pain Drugs Facing Challenges
  • 10.10 New Opioids Providing Opportunities for Growth
  • 10.11 The Potential Use of Cannabinoids In Pain Relief

11. Qualitative Analysis for the Global Pain Relieving Drugs Market, 2017-2027

  • 11.1 Market Factors Influencing the Pain Relieving Drugs Market
  • 11.2 SWOT Analysis of the Pain Relieving Drugs Market, 2016-2027
    • 11.2.1 Strengths
      • 11.2.1.1 Cost Effectiveness: A Major Driver for Growth
      • 11.2.1.2 Promising Candidates in the R&D Pipeline
    • 11.2.2 Weaknesses
      • 11.2.2.1 Product Withdrawals and Slow Regulatory Approvals
      • 11.2.2.2 Concerns Over Drug Side Effects
      • 11.2.2.3 Education in Pain Management is a Key Unmet Need
    • 11.2.3 Opportunities
      • 11.2.3.1 Reformulations of Existing Drugs Will Drive Market Growth
      • 11.2.3.2 Reforms in Narcotics Offer Growth Opportunities
      • 11.2.3.3 Ageing Population - Growth Driver for Pain Relieving Drugs
      • 11.2.3.4 The Economic Benefits of Expansion Into Emerging Markets
      • 11.2.3.5 OTC Switching May Help To Delay Generic Erosion
    • 11.2.4 Threats
      • 11.2.4.1 Patent Expiries Will Lead to Generic Competition
      • 11.2.4.2 Regulatory and Pricing Scrutiny Could Suffocate Market Growth
      • 11.2.4.3 Inadequate Reimbursement Levels: A Potential Restraint On Market Growth
  • 11.3 STEP Analysis of the Pain Relieving Drugs Market, 2016-2027
    • 11.3.1 Social Factors Affecting the Pain Relieving Drugs Market
    • 11.3.2 Technological Factors Affecting the Pain Relieving Drugs Market
    • 11.3.3 Economic Factors Affecting the Pain Relieving Drugs Market
    • 11.3.4 Political Factors Affecting the Pain Relieving Drugs Market

12. Conclusions

  • 12.1 Market Overview
  • 12.2 The Likely Impacts of Patent and Exclusivity Expiries on Pain Relieving Drugs
  • 12.3 Major Growth Drivers for Pain Relieving Drugs
  • 12.4 Under-Served Needs in Neuropathic Pain Leaves Room for Growth
  • 12.5 The Narcotic Pain Relieving Drugs Market: Its Driving and Restraining Factors
  • 12.6 Botox Approval Expected to Boost Anti-Migraine Submarket
  • 12.7 The Rise of Biological Anti-Arthritic Pain Drugs
  • 12.8 Emerging Markets Set To Drive Steer Market Forward
  • 12.9 What Does The Future Hold For Pain Relieving Drugs?
  • Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Figures

  • Figure 1.1 Global Pain Relieving Drugs Market: Submarkets, 2017
  • Figure 2.1 Categories of Pain
  • Figure 3.1 The Global Pain Relieving Drugs Market: Revenue ($bn) by Sector, 2016
  • Figure 3.2 The Global Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 3.3 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2016-2021
  • Figure 3.4 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2021-2027
  • Figure 3.5 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2016-2027
  • Figure 3.6 The Global Pain Relieving Drugs Market: Revenue ($bn) by Sector, 2016
  • Figure 3.7 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2016
  • Figure 3.7 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2021
  • Figure 3.8 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2027
  • Figure 4.1 The Global Narcotic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016
  • Figure 4.2 The Global Narcotic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 4.3 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016
  • Figure 4.4 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2021
  • Figure 4.5 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2027
  • Figure 4.6 Opana ER: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 4.7 Opana ER: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 4.8 Duragesic: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 4.9 Duragesic: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 4.10 Oxycontin: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 4.11 Ultram: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 4.12 Zaldiar/Ixprim: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 4.13 Zaldiar/Ixprim: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 4.14 Other Narcotic Pain Relieving Drugs: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 5.1 The Global Non-Narcotic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016
  • Figure 5.2 The Global Non-Narcotic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 5.3 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016
  • Figure 5.4 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2021
  • Figure 5.5 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2027
  • Figure 5.6 Aspirin and Aspirin Cardio: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 5.7 Aspirin (Bayer): Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 5.8 Panadol (GSK): Historical Sales ($bn, AGR%), 2014-2016
  • Figure 5.9 Panadol (GSK): Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 5.10 Advil: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 5.11 Tylenol: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 5.12 Other Non-Narcotic Pain Drugs: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 6.1 The Global Neuropathic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016
  • Figure 6.2 The Global Neuropathic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 6.3 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016
  • Figure 6.4 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2021
  • Figure 6.5 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2027
  • Figure 6.6 Lidoderm: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 6.7 Lidoderm: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 6.8 Lyrica: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 6.9 Lyrica: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 6.10 Cymbalta: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 6.11 Cymbalta: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 6.12 Neurontin: Historical Sales ($bn, AGR%), 2014-2017
  • Figure 6.13 Neurontin: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 6.14 Nucynta: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 6.15 Nucynta: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 6.16 Other Neuropathic Pain Relieving Drugs: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 7.1 The Global Anti-Migraine Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016
  • Figure 7.2 The Global Anti-Migraine Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 7.3 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016
  • Figure 7.4 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2021
  • Figure 7.5 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2027
  • Figure 7.6 Relpax: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 7.7 Relpax: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 7.8 Maxalt: Historical Sales ($m, AGR%), 2014-2016
  • Figure 7.9 Maxalt: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 7.10 Imitrex/Imigran: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 7.11 Imitrex/Imigran: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 7.12 Zomig: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 7.13 Zomig: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 7.14 Botox (Allergan): Historical Sales ($bn, AGR%), 2014-2016
  • Figure 7.15 Botox: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 7.16 Treximet: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 7.17 Treximet: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 7.18 Axert: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 7.19 Axert: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 7.20 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 8.1 The Global Anti-Arthritic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016
  • Figure 8.2 The Global Anti-Arthritis Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 8.3 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016
  • Figure 8.4 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2021
  • Figure 8.5 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by leading Drugs, 2027
  • Figure 8.6 Humira: Historical Sales ($bn), 2014-2016
  • Figure 8.7 Humira: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 8.8 Enbrel: Historical Sales ($bn, AGR%), 2014-2016
  • Figure 8.9 Enbrel: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 8.10 Remicade: Historical Sales ($bn) by Company, 2014-2016
  • Figure 8.11 Remicade: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 8.12 Voltaren: Historical Sales ($bn, AGR %), 2014-2016
  • Figure 8.14 Rituxan: Historical Sales ($bn), 2014-2016
  • Figure 8.15 Rituxan: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 8.16 Celebrex: Historical Sales ($bn), 2014-2016
  • Figure 8.17 Celebrex: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 8.18 Arcoxia: Historical Sales ($bn), 2014-2016
  • Figure 8.19 Arcoxia: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 8.20 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast ($bn, AGR%), 2016-2027
  • Figure 9.1 The Global Pain Relieving Drugs Market: Market Size ($bn) by Region, 2016
  • Figure 9.2 US, EU5, China, and Japan Pain Relieving Drugs Market: Market Forecast ($bn), 2016-2027
  • Figure 9.3 Russia, Brazil, India, and Rest of World Pain Relieving Drugs Markets: Market Forecasts ($bn), 2016-2027
  • Figure 9.4 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2016-2021
  • Figure 9.5 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2021-2027
  • Figure 9.6 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2016-2027
  • Figure 9.7 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2016
  • Figure 9.8 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2021
  • Figure 9.9 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2027
  • Figure 9.10 US Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.11 The EU5 Pain Relieving Drugs Market: Revenues ($bn) by Country, 2016
  • Figure 9.12 Germany, France, UK, Italy, and Spain Pain Relieving Drugs Market: Market Forecast ($bn), 2016-2027
  • Figure 9.13 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2016
  • Figure 9.14 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2021
  • Figure 9.15 The EU5 Pain Relieving Drugs Market: Market Shares (%) by Country, 2027
  • Figure 9.16 German Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.17 The UK Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.18 French Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.19 Italian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.20 Spanish Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.21 Japanese Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.22 Chinese Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.23 Brazilian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.24 Indian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.25 Russian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 9.26 Rest of the World Pain Relieving Drugs Market: Market Forecast ($bn, AGR%), 2016-2027
  • Figure 11.1 Global Population Forecast: Total Population (m) and Over-65 Population (m), 2016, 2021, 2027, 2030
  • Figure 12.1 Pain Relieving Drugs: Market Forecast ($bn)
  • Figure 12.2 Pain Relieving Drugs: Market Forecast ($bn) by Sector, 2016-2027

List of Tables

  • Table 1.1 (Sample) Global Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Region, 2016-2027
  • Table 2.1 Comparison of Acute and Chronic Pain
  • Table 2.2 Therapeutic Classes In Pain Management
  • Table 3.1 The Global Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Sector, 2016
  • Table 3.2 The Global Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Sector, 2016-2027
  • Table 3.3 The Global Pain Relieving Drugs Market Forecast: CAGR (%) by Sector, 2016-2021, 2021-2027, 2016-2027
  • Table 3.4 The Global Pain Relieving Drugs Market: Revenue ($bn) by Sector, 2016, 2021, 2027
  • Table 3.5 The Global Pain Relieving Drugs Market: Market Share (%) by Sector, 2016, 2021, 2027
  • Table 4.1 The Global Narcotic Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2016
  • Table 4.2 The Global Narcotic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2016-2027
  • Table 4.3 The Narcotic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016, 2021, 2027
  • Table 4.4 The Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
  • Table 4.5 Opana ER: Historical Sales ($bn, AGR%), 2014-2016
  • Table 4.6 Opana ER: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 4.7 Duragesic: Historical Sales ($bn, AGR%), 2014-2016
  • Table 4.8 Duragesic: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 4.9 Oxycontin: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 4.10 Ultram: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 4.11 Zaldiar/Ixprim: Historical Sales ($bn, AGR%), 2014-2016
  • Table 4.12 Zaldiar/Ixprim: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 4.13 Other Narcotic Pain Relieving Drugs: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.1 The Global Non-Narcotic Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2016
  • Table 5.2 The Global Non-Narcotic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2016-2027
  • Table 5.3 The Non-Narcotic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016, 2021, 2027
  • Table 5.4 The Non-Narcotic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
  • Table 5.5 Aspirin and Aspirin Cardio: Historical Sales ($bn, AGR%), 2014-2016
  • Table 5.6 Aspirin (Bayer): Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.7 Selected Panadol Formulations
  • Table 5.8 Panadol (GSK): Historical Sales ($bn, AGR%), 2014-2016
  • Table 5.9 Panadol (GSK): Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.10 Selected Advil Products and Product Details
  • Table 5.11 Advil: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.12 Selected Tylenol Products and Product Details
  • Table 5.13 Tylenol: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.14 Other Non-Narcotic Pain Drugs: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 6.1 Key Drug Indications for Neuropathic Pain
  • Table 6.2 Key FDA-Approved Drugs Indicated for Neuropathic Pain
  • Table 6.3 The Global Neuropathic Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2016
  • Table 6.4 The Global Neuropathic Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2016-2027
  • Table 6.5 The Neuropathic Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016, 2021, 2027
  • Table 6.6 The Neuropathic Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
  • Table 6.7 Lidoderm: Historical Sales ($bn, AGR%), 2014-2016
  • Table 6.8 Lidoderm: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 6.9 Lyrica: Historical Sales ($bn, AGR%), 2014-2017
  • Table 6.10 Lyrica: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 6.11 Cymbalta: Historical Sales ($bn, AGR%), 2014-2016
  • Table 6.12 Cymbalta: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 6.13 Neurontin: Historical Sales ($bn, AGR%), 2014-2016
  • Table 6.14 Neurontin: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 6.15 Nucynta: Historical Sales ($bn, AGR%), 2014-2016
  • Table 6.16 Nucynta: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 6.17 Other Neuropathic Pain Relieving Drugs: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 7.1 The Global Anti-Migraine Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2016
  • Table 7.2 The Global Anti-Migraine Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 7.3 The Anti-Migraine Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016, 2021, 2027
  • Table 7.4 The Anti-Migraine Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
  • Table 7.5 Relpax: Historical Sales ($bn, AGR%), 2014-2016
  • Table 7.6 Relpax: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 7.7 Maxalt: Historical Sales ($bn, AGR%), 2014-2016
  • Table 7.8 Maxalt: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 7.9 Imitrex/Imigran: Historical Sales ($bn, AGR%), 2008-2013
  • Table 7.10 Imitrex/Imigran: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 7.11 Zomig: Historical Sales ($bn, AGR%), 2014-2016
  • Table 7.12 Zomig: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 7.13 Botox (Allergan): Historical Sales ($bn, AGR%), 2014-2016
  • Table 7.14 Botox: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 7.15 Treximet: Historical Sales ($bn, AGR%), 2014-2016
  • Table 7.16 Treximet: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 7.17 Axert: Historical Sales ($bn, AGR%), 2014-2016
  • Table 7.18 Axert: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 7.19 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 8.1 Selected Examples of Anti-Arthritic Pain Relieving Drugs
  • Table 8.2 The Global Anti-Arthritic Pain Relieving Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2016
  • Table 8.3 The Global Anti-Arthritis Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Leading Drugs, 2016-2027
  • Table 8.4 The Anti-Arthritis Pain Relieving Drugs Market: Revenue ($bn) by Leading Drugs, 2016, 2021, 2027
  • Table 8.5 The Anti-Arthritis Pain Relieving Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
  • Table 8.6 Humira: Historical Sales ($bn, AGR%), 2014-2016
  • Table 8.7 Humira: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 8.8 Enbrel: Historical Sales ($bn, AGR%, 2014-2016
  • Table 8.9 Enbrel: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 8.10 Remicade: Historical Sales ($bn, AGR%) by Company, 2014-2016
  • Table 8.11 Remicade: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 8.12 Voltaren: Historical Sales ($bn, AGR%), 2014-2016
  • Table 8.13 Voltaren: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 8.14 Rituxan: Historical Sales ($bn, AGR%), 2014-2016
  • Table 8.15 Rituxan: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 8.16 Celebrex: Historical Sales ($bn, AGR%), 2014-2016
  • Table 8.17 Celebrex: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 8.18 Arcoxia: Historical Sales ($bn, AGR%), 2014-2016
  • Table 8.19 Arcoxia: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 8.20 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.1 The Global Pain Relieving Drugs Market: Market Size ($bn) and Market Share (%) by Region, 2016
  • Table 9.2 Global Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%) by Region, 2016-2027
  • Table 9.3 Pain Relieving Drugs Market Forecast: CAGR (%) by Region, 2016-2021, 2021-2027, and 2016-2027
  • Table 9.4 Pain Relieving Drugs Market Forecast: Market Shares (%) by Region, 2016, 2021, 2027
  • Table 9.5 US Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.6 The EU5 Pain Relieving Drugs Market: Revenue ($bn) and Market Share (%) by Country, 2013
  • Table 9.7 EU5 Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.8 The EU5 Pain Relieving Drugs Market: Market Share (%) by Country, 2016, 2021, 2027
  • Table 9.9 The German Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.10 The UK Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2026
  • Table 9.11 French Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.12 Italian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.13 Spanish Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.14 Japanese Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.15 Chinese Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.16 Brazilian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.17 Indian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.18 Russian Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 9.19 Rest of the World Pain Relieving Drugs Market: Market Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 10.1 R&D Pipeline for Narcotic Pain Relieving Drugs
  • Table 10.2 R&D Pipeline for Non-Narcotic Pain Relieving Drugs
  • Table 10.3 R&D Pipeline for Neuropathic Pain Relieving Drugs
  • Table 10.4 R&D Pipeline for Anti-Migraine Pain Relieving Drugs
  • Table 10.5 R&D Pipeline for Anti-Arthritis Pain Relieving Drugs
  • Table 11.1 Pain Relieving Drugs: Market Drivers and Restraints 2016-2027
  • Table 11.2 SWOT Analysis of the Pain Relieving Drugs Market, 2016-2027
  • Table 11.3 Global Population Forecast: Total Population (m) and Over-65 Population (m, %), 2016, 2021, 2027, 2030
  • Table 11.4 STEP Analysis of the Pain Relieving Drugs Market, 2016-2027
  • Table 12.1 Pain Relieving Drugs: Market Forecast ($bn, CAGR%)
  • Table 12.2 Pain Relieving Drugs: Market Forecast ($bn) by Sector, 2016, 2021, 2027
  • Table 12.3 Global Pain Relieving Drugs: Market Shares (%) by Region, 2016, 2021, 2027

Companies Listed

  • AB Science
  • Abbott
  • AcelRx Pharmaceuticals
  • Actavis
  • Acura
  • Alder Biopharmaceuticals Inc
  • Alkem Laboratories Ltd.
  • Allergan
  • AlphaPharm
  • AlZA Corporation
  • Amgen
  • Apotex Corp.
  • Apotex Inc.
  • Arcion Therapeutics
  • Ascend Laboratories
  • AstraZeneca
  • Avanir Pharmaceuticals
  • Bayer
  • BioDelivery Sciences
  • Biogen Idec
  • Biovail Corporation
  • Boehringer Ingelheim
  • Boston Children Hospital
  • Bristol-Myers Squibb (BMS)
  • Centocor Ortho Biotech
  • China Aoxing
  • Chugai
  • Cilag GmbH
  • Cipla
  • CK Life Sciences
  • Collegium Pharmaceuticals
  • CoLucid Pharmaceuticals Inc
  • Dr Reddy's
  • Durect
  • Eisai
  • Eli Lilly
  • Endo Pharmaceuticals
  • FDA
  • Forest
  • Genentech
  • Genmab
  • GlaxoSmithKline (GSK)
  • Grünenthal Group
  • Horizon Pharma
  • Human Genome Sciences
  • Immune Pharmaceuticals
  • Immunex
  • Impax Laboratories
  • Impax Pharmaceuticals
  • Insys Therapeutics
  • Ipsen
  • IVAX Pharmaceuticals
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • Kaiser Foundation Health Plan, Inc.
  • King Pharmaceuticals
  • Kyorin
  • Lexicon Pharmaceuticals
  • Lundbeck
  • Lupin Pharmaceuticals USA
  • McNeil Consumer Healthcare
  • Merck & Co.
  • Merck Serono
  • Mitsubishi Tanabe Pharma
  • Monsanto
  • Mundipharma
  • Mylan
  • NeurAxon
  • NeurogesX
  • Neurotune
  • Newron
  • NICE
  • NicOx
  • Novartis
  • Nupathe Inc.
  • Nuvo Research
  • Omeros
  • Ortho-McNeil, Inc.
  • Pacira Pharmaceuticals
  • Pain Therapeutics
  • Paion
  • Par Pharmaceuticals
  • Pfizer
  • Pfizer
  • PLx Pharma
  • Pozen Pharmaceutical
  • Proteus SA
  • Purdue Pharma
  • QRx Pharma
  • Roche
  • Roxane Laboratories
  • Samsung
  • Sandoz
  • Schering-Plough
  • Shionogi & Co Ltd.
  • Shire
  • Skyepharma
  • Spinifex Pharmaceuticals
  • Sun Pharmaceuticals
  • Syntaxin
  • Takeda
  • Teikoku
  • Teva
  • UCB
  • US Justice Department
  • US WorldMeds
  • Valeant Pharmaceuticals
  • Vapogenix Inc
  • Vitality Biopharma Inc.
  • Watson Pharmaceuticals
  • WEX Pharmaceuticals
  • WHO
  • Wyeth
  • Zars Pharmaceuticals
  • Zogenix
Back to Top